Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Intrinsic Value
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. [ Read More ]
The intrinsic value of one ARCT stock under the Base Case scenario is 114.87 USD. Compared to the current market price of 32.86 USD, Arcturus Therapeutics Holdings Inc is Undervalued by 71%.
Valuation Backtest
Arcturus Therapeutics Holdings Inc
Run backtest to discover the historical profit from buying and selling ARCT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Arcturus Therapeutics Holdings Inc's business.
What risks and challenges
does Arcturus Therapeutics Holdings Inc face in the near future?
Summarize the latest earnings report
of Arcturus Therapeutics Holdings Inc.
Provide P/E
for Arcturus Therapeutics Holdings Inc and its competitors.
Balance Sheet Decomposition
Arcturus Therapeutics Holdings Inc
Current Assets | 386.6m |
Cash & Short-Term Investments | 292m |
Receivables | 32.1m |
Other Current Assets | 62.5m |
Non-Current Assets | 42.8m |
PP&E | 40.9m |
Other Non-Current Assets | 1.9m |
Current Liabilities | 78.9m |
Accounts Payable | 5.3m |
Accrued Liabilities | 31.9m |
Other Current Liabilities | 41.7m |
Non-Current Liabilities | 68.9m |
Other Non-Current Liabilities | 68.9m |
Earnings Waterfall
Arcturus Therapeutics Holdings Inc
Revenue
|
169.9m
USD
|
Operating Expenses
|
-245m
USD
|
Operating Income
|
-75.1m
USD
|
Other Expenses
|
48.5m
USD
|
Net Income
|
-26.6m
USD
|
Free Cash Flow Analysis
Arcturus Therapeutics Holdings Inc
What is Free Cash Flow?
ARCT Profitability Score
Profitability Due Diligence
Arcturus Therapeutics Holdings Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Arcturus Therapeutics Holdings Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ARCT Solvency Score
Solvency Due Diligence
Arcturus Therapeutics Holdings Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Arcturus Therapeutics Holdings Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARCT Price Targets Summary
Arcturus Therapeutics Holdings Inc
According to Wall Street analysts, the average 1-year price target for ARCT is 68.98 USD with a low forecast of 18.18 USD and a high forecast of 147 USD.
Ownership
ARCT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ARCT Price
Arcturus Therapeutics Holdings Inc
Average Annual Return | 91.55% |
Standard Deviation of Annual Returns | 203.65% |
Max Drawdown | -90% |
Market Capitalization | 881.6m USD |
Shares Outstanding | 26 915 200 |
Percentage of Shares Shorted | 20.97% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. The company is headquartered in San Diego, California and currently employs 177 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The firm's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).
Contact
IPO
Employees
Officers
The intrinsic value of one ARCT stock under the Base Case scenario is 114.87 USD.
Compared to the current market price of 32.86 USD, Arcturus Therapeutics Holdings Inc is Undervalued by 71%.